Chiasma, Inc. (CHMA) Director Scott Minick Acquires 25,000 Shares
Chiasma, Inc. (NASDAQ:CHMA) Director Scott Minick purchased 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 21st. The stock was bought at an average cost of $2.37 per share, for a total transaction of $59,250.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Scott Minick also recently made the following trade(s):
- On Wednesday, September 20th, Scott Minick purchased 15,000 shares of Chiasma stock. The stock was bought at an average cost of $2.38 per share, for a total transaction of $35,700.00.
Shares of Chiasma, Inc. (NASDAQ:CHMA) traded down 2.04% during mid-day trading on Friday, reaching $2.40. The company’s stock had a trading volume of 32,511 shares. Chiasma, Inc. has a 12 month low of $1.55 and a 12 month high of $3.71. The company has a 50 day moving average of $2.31 and a 200-day moving average of $2.31. The firm’s market capitalization is $58.46 million.
TRADEMARK VIOLATION NOTICE: “Chiasma, Inc. (CHMA) Director Scott Minick Acquires 25,000 Shares” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/23/chiasma-inc-chma-director-scott-minick-acquires-25000-shares.html.
Separately, ValuEngine raised Chiasma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.